Transarterial chemoembolization (TACE) with irinotecan eluting beads (DEBIRI) may be a safe palliative treatment with fewer serious adverse effects (SAEs). We aimed to establish the …

Dec 6, 2023 · Drug-eluting bead, irinotecan (DEBIRI) is a consolidative therapy designed to treat colorectal liver metastases by using transarterial chemoembolization (TACE); the primary …

The DEBIRI technique consists in intrahepatic embolization of metastases with non-absorbable beads (75-150 μm and 100-300 μm) preloaded with irinotecan, carried near tumour using a …

Feb 16, 2013 · For patients with unresectable colorectal liver metastasis (CRLM), transarterial embolization with the use of drug-eluting beads with irinotecan (DEBIRI) represents a novel …

Jun 8, 2020 · Chemo-embolisation with drug-eluting beads loaded with irinotecan (DEBIRI) increased survival as compared with intravenous irinotecan in chemorefractory patients with …

Mar 1, 2014 · Transcatheter hepatic arterial administration of irinotecan-loaded drug-eluting beads (DEBIRI) is used to treat liver-only or liver-dominant metastatic disease from colorectal cancer …

This study showed a statistically significant difference between DEBIRI and FOLFIRI for overall survival (7 months), progression-free survival (3 months) and quality of life (5 months). In …

DEBIRI can be used safely in the palliative treatment of hepatic metastases from mCRC. It is a well-tolerated feasible treatment option with a low AE profile.

PURPOSE: For patients with unresectable colorectal liver metastasis (CRLM), transarterial embolization with the use of drug-eluting beads with irinotecan (DEBIRI) represents a novel …

Drug-eluting beads, Irinotecan (DEBIRI), is a new technique that involves embolisation of the feeding vessels to the tumour and delivering irinotecan for its chemotherapeutic effects. A …